191 related articles for article (PubMed ID: 16189155)
1. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas.
Gong J; Chen N; Zhou Q; Yang B; Wang Y; Wang X
J Clin Pathol; 2005 Oct; 58(10):1081-5. PubMed ID: 16189155
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?
De Panfilis G; Ferrari D; Santoro S; Ricci R; Lombardi M; Pedrazzi G; Pepe C; Cortelazzi C; Santini M
Br J Dermatol; 2009 Mar; 160(3):600-8. PubMed ID: 19183173
[TBL] [Abstract][Full Text] [Related]
3. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
[TBL] [Abstract][Full Text] [Related]
6. Gene expression patterns in melanocytic cells: candidate markers for early stage and malignant transformation.
Meije CB; Hakvoort TB; Swart GW; Westerhof W; Lamers WH; Das PK
J Pathol; 2002 Jan; 196(1):51-8. PubMed ID: 11748642
[TBL] [Abstract][Full Text] [Related]
7. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin/catenin complex in benign and malignant melanocytic lesions.
Silye R; Karayiannakis AJ; Syrigos KN; Poole S; van Noorden S; Batchelor W; Regele H; Sega W; Boesmueller H; Krausz T; Pignatelli M
J Pathol; 1998 Dec; 186(4):350-5. PubMed ID: 10209482
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.
Paraoan L; Gray D; Hiscott P; Ebrahimi B; Damato B; Grierson I
Exp Eye Res; 2006 Oct; 83(4):911-9. PubMed ID: 16784742
[TBL] [Abstract][Full Text] [Related]
10. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas.
Dynek JN; Chan SM; Liu J; Zha J; Fairbrother WJ; Vucic D
Cancer Res; 2008 May; 68(9):3124-32. PubMed ID: 18451137
[TBL] [Abstract][Full Text] [Related]
11. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
12. [Nevus associated malignant melanomas--diagnostic validation and prognosis].
Stadler R; Garbe C
Hautarzt; 1991 Jul; 42(7):424-9. PubMed ID: 1938395
[TBL] [Abstract][Full Text] [Related]
13. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
14. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
15. Cadherin expression in melanocytic naevi and malignant melanomas.
Cowley GP; Smith ME
J Pathol; 1996 Jun; 179(2):183-7. PubMed ID: 8758211
[TBL] [Abstract][Full Text] [Related]
16. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
18. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of heat shock protein 105 in melanoma and melanocytic naevi.
Muchemwa FC; Nakatsura T; Fukushima S; Nishimura Y; Kageshita T; Ihn H
Melanoma Res; 2008 Jun; 18(3):166-71. PubMed ID: 18477890
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma.
Lederman M; Meir T; Zeschnigk M; Pe'er J; Chowers I
Curr Eye Res; 2008 Oct; 33(10):876-84. PubMed ID: 18853322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]